韩国类风湿关节炎与帕金森病风险
这项回顾性队列研究利用韩国国民健康保险服务数据库,纳入54680例类风湿关节炎(RA)患者及273400例年龄性别匹配对照,中位随访4.3年。结果显示RA患者帕金森病(PD)风险较对照升高(HR 1.74,95%CI 1.52-1.99),血清阳性RA风险升高(aHR 1.95,95%CI 1.68-2.26),血清阴性RA无显著升高(aHR 1.20,95%CI 0.91-1.57)。作者认为医生应意识到RA患者PD风险升高,并在出现无滑膜炎的早期运动症状时及时转诊神经科。
要点
- RA患者帕金森病风险较非RA对照升高(HR 1.74,95%CI 1.52-1.99)。
- 血清阳性RA患者PD风险升高(aHR 1.95,95%CI 1.68-2.26),血清阴性RA无显著升高(aHR 1.20,95%CI 0.91-1.57)。
- 血清阳性RA较血清阴性RA的PD风险更高(aHR 1.61,95%CI 1.20-2.16)。
核心结论
- 本研究中类风湿关节炎与帕金森病风险升高相关,且类风湿关节炎血清阳性赋予帕金森病风险进一步升高。
研究设计与样本
- 回顾性队列研究,使用韩国国民健康保险服务数据库收集2010至2017年入组、随访至2019年的类风湿关节炎患者数据,中位随访4.3年(IQR 2.6-6.4,1年滞后后)。
- 共识别119788例新诊断类风湿关节炎患者(血清阳性83064例,血清阴性36724例),其中64457例在诊断前2年内接受国家健康体检。
- 应用排除标准(如年龄<40岁、其他风湿病、既往帕金森病)后纳入54680例(血清阳性39010例,血清阴性15670例),并纳入1:5年龄性别匹配的无类风湿关节炎对照共273400例。
主要发现
- 共分析328080人(平均[SD]年龄58.6[10.1]岁,女性74.9%,男性25.1%),1093人发生帕金森病(对照803例,类风湿关节炎290例)。
- 类风湿关节炎患者帕金森病风险较对照升高1.74倍(95%CI 1.52-1.99)。
- 血清阳性类风湿关节炎患者帕金森病风险升高(aHR 1.95,95%CI 1.68-2.26),血清阴性类风湿关节炎患者无显著升高(aHR 1.20,95%CI 0.91-1.57)。
- 与血清阴性类风湿关节炎组相比,血清阳性组帕金森病风险更高(aHR 1.61,95%CI 1.20-2.16)。
- 协变量对帕金森病风险无显著交互作用。
关键数值与推荐
- 类风湿关节炎定义:血清阳性使用国际疾病分类第十版编码M05,血清阴性使用M06(除外M06.1和M06.4),并需处方任何改善病情抗风湿药及纳入韩国罕见难治性疾病项目。
临床怎么用
- 作者认为,医生应意识到类风湿关节炎患者帕金森病风险升高,并在出现无滑膜炎的帕金森病早期运动症状时及时转诊神经科医生。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Although it has been postulated that chronic inflammation caused by rheumatoid arthritis (RA) contributes to the development of Parkinson disease (PD), the association between these 2 conditions has yet to be determined. OBJECTIVE: To evaluate the association between RA and subsequent PD risk. DESIGN, SETTING, AND PARTICIPANTS: This retrospective cohort study used the Korean National Health Insurance Service database to collect population-based, nationally representative data on patients with RA enrolled from 2010 to 2017 and followed up until 2019 (median follow-up, 4.3 [IQR, 2.6-6.4] years after a 1-year lag). A total of 119 788 patients who were first diagnosed with RA (83 064 with seropositive RA [SPRA], 36 724 with seronegative RA [SNRA]) were identified during the study period and included those who underwent a national health checkup within 2 years before the RA diagnosis date (64 457 patients). After applying exclusion criteria (eg, age <40 years, other rheumatic diseases, previous PD), 54 680 patients (39 010 with SPRA, 15 670 with SNRA) were included. A 1:5 age- and sex-matched control group of patients without RA was also included for a total control population of 273 400. EXPOSURES: Rheumatoid arthritis as defined using International Classification of Diseases, Tenth Revision codes M05 for SPRA and M06 (except M06.1 and M06.4) for SNRA; prescription of any disease-modifying antirheumatic drug; and enrollment in the Korean Rare and Intractable Diseases program. MAIN OUTCOMES AND MEASURES: The main outcome was newly diagnosed PD. Data were analyzed from May 10 through August 1, 2022, using Cox proportional hazards regression analyses. RESULTS: From the 328 080 individuals analyzed (mean [SD] age, 58.6 [10.1] years; 74.9% female and 25.1% male), 1093 developed PD (803 controls and 290 with RA). Participants with RA had a 1.74-fold higher risk of PD vs controls (95% CI, 1.52-1.99). An increased risk of PD was found in patients with SPRA (adjusted hazard ratio [aHR], 1.95; 95% CI, 1.68-2.26) but not in patients with SNRA (aHR, 1.20; 95% CI, 0.91-1.57). Compared with the SNRA group, those with SPRA had a higher risk of PD (aHR, 1.61; 95% CI, 1.20-2.16). There was no significant interaction between covariates on risk of PD. CONCLUSIONS AND RELEVANCE: In this study, RA was associated with an increased risk of PD, and seropositivity of RA conferred an augmented risk of PD. The findings suggest that physicians should be aware of the elevated risk of PD in patients with RA and promptly refer patients to a neurologist at onset of early motor symptoms of PD without synovitis.
引用
- Kang J, Eun Y, Jang W, et al. Rheumatoid Arthritis and Risk of Parkinson Disease in Korea. JAMA Neurol. 2023. PMID: 37126341. doi:10.1001/jamaneurol.2023.0932
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。